MediXall (MDXL) Return on Equity (2019 - 2024)
MediXall's Return on Equity history spans 6 years, with the latest figure at 0.39% for Q3 2024.
- For Q3 2024, Return on Equity fell 58.0% year-over-year to 0.39%; the TTM value through Sep 2024 reached 0.39%, down 58.0%, while the annual FY2023 figure was 0.9%, 251.0% down from the prior year.
- Return on Equity reached 0.39% in Q3 2024 per MDXL's latest filing, down from 0.46% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 50.67% in Q4 2021 to a low of 27.7% in Q3 2021.
- Average Return on Equity over 5 years is 1.3%, with a median of 0.57% recorded in 2024.
- Peak YoY movement for Return on Equity: soared 6130bps in 2021, then plummeted -4859bps in 2022.
- A 5-year view of Return on Equity shows it stood at 10.63% in 2020, then surged by 577bps to 50.67% in 2021, then tumbled by -96bps to 2.07% in 2022, then tumbled by -63bps to 0.78% in 2023, then tumbled by -50bps to 0.39% in 2024.
- Per Business Quant, the three most recent readings for MDXL's Return on Equity are 0.39% (Q3 2024), 0.46% (Q2 2024), and 0.57% (Q1 2024).